FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3124307256> ?p ?o ?g. }

• W3124307256 abstract "Abstract Background In the era of anti-retroviral therapy (ART), the plasma HIV viral load (VL) is an important primary indicator for monitoring the HIV treatment response. To optimize the clinical management of HIV/AIDS patients, we investigated VL high-risk events related to virological failure (VF) and further explored the preventive factors of VL high-risk events. Methods The data were derived from China’s HIV/AIDS Comprehensive Response Information Management System. HIV infected patients who initiated or received ART in Guangxi between 2003 and 2019 were included. The contributions of VL after 6 months of ART to VF and AIDS-related death were analysed by Kaplan-Meier curves, log-rank tests and Cox regression analyses. Both descriptive analyses and bivariate logistic regression were employed to further explore the preventive factors related to VL high-risk events of VF. Results The cumulative rates of VF in the high low-level viremia group (high LLV) ( χ 2 = 18.45; P < 0.001) and non-suppressed group ( χ 2 = 82.99; P < 0.001) were significantly higher than those in the viral suppression (VS) group. Therefore, the VL high-risk events of VF was defined as highest VL > 200 copies/ml after 6 months of ART. Compared with the VS group, the adjusted hazard risk was 7.221 ( 95% CI : 2.668; 19.547) in the high LLV group and 8.351 ( 95% CI : 4.253; 16.398) in the non-suppressed group. Compared with single patients, married or cohabiting ( AOR = 0.591; 95% CI : 0.408, 0.856) and divorced or separated ( AOR = 0.425, 95% CI : 0.207, 0.873) patients were negatively associated with VL high-risk events. So were patients acquired HIV homosexually ( AOR = 0.572; 95% CI : 0.335, 0.978). However, patients who had ART modification were 1.728 times ( 95% CI : 1.093, 2.732) more likely to have VL high-risk events, and patients who used cotrimoxazole during ART were 1.843 times ( 95% CI : 1.271, 2.672) more likely to have VL high-risk events. Conclusions A VL greater than 200 copies/ml is a VL high-risk event for VF. Intervention measurements should be adopted to optimize the surveillance of ART in patients who are single or widowed, who have ART modification, and who use cotrimoxazole during ART." @default.
• W3124307256 created "2021-02-01" @default.
• W3124307256 creator A5018201073 @default.
• W3124307256 creator A5018716888 @default.
• W3124307256 creator A5024110076 @default.
• W3124307256 creator A5031888627 @default.
• W3124307256 creator A5032787375 @default.
• W3124307256 creator A5043942510 @default.
• W3124307256 creator A5058907248 @default.
• W3124307256 creator A5059240782 @default.
• W3124307256 creator A5069849278 @default.
• W3124307256 creator A5070028057 @default.
• W3124307256 creator A5073588989 @default.
• W3124307256 date "2021-05-18" @default.
• W3124307256 modified "2023-10-17" @default.
• W3124307256 title "Predictive factors of viral load high-risk events for virological failure in HIV/AIDS patients receiving long-term antiviral therapy" @default.
• W3124307256 cites W1514920117 @default.
• W3124307256 cites W1562756213 @default.
• W3124307256 cites W1975174027 @default.
• W3124307256 cites W1983341851 @default.
• W3124307256 cites W2000962191 @default.
• W3124307256 cites W2001776291 @default.
• W3124307256 cites W2008729344 @default.
• W3124307256 cites W2010696953 @default.
• W3124307256 cites W2015068616 @default.
• W3124307256 cites W2018340707 @default.
• W3124307256 cites W2025582221 @default.
• W3124307256 cites W2046760717 @default.
• W3124307256 cites W2078009105 @default.
• W3124307256 cites W2081757964 @default.
• W3124307256 cites W2115053153 @default.
• W3124307256 cites W2115919377 @default.
• W3124307256 cites W2136381344 @default.
• W3124307256 cites W2149606648 @default.
• W3124307256 cites W2153840871 @default.
• W3124307256 cites W2157981460 @default.
• W3124307256 cites W2159324987 @default.
• W3124307256 cites W2182777591 @default.
• W3124307256 cites W2227225214 @default.
• W3124307256 cites W2290965057 @default.
• W3124307256 cites W2296505979 @default.
• W3124307256 cites W2331047565 @default.
• W3124307256 cites W2475857717 @default.
• W3124307256 cites W2518013305 @default.
• W3124307256 cites W2740086757 @default.
• W3124307256 cites W2769261452 @default.
• W3124307256 cites W2769267084 @default.
• W3124307256 cites W2795997357 @default.
• W3124307256 cites W2850724727 @default.
• W3124307256 cites W2854369675 @default.
• W3124307256 cites W2884073176 @default.
• W3124307256 cites W2905487963 @default.
• W3124307256 cites W2908033759 @default.
• W3124307256 cites W4240153861 @default.
• W3124307256 cites W4240243247 @default.
• W3124307256 doi "https://doi.org/10.1186/s12879-021-06162-z" @default.
• W3124307256 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8130293" @default.
• W3124307256 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34006230" @default.
• W3124307256 hasPublicationYear "2021" @default.
• W3124307256 type Work @default.
• W3124307256 sameAs 3124307256 @default.
• W3124307256 citedByCount "10" @default.
• W3124307256 countsByYear W31243072562022 @default.
• W3124307256 countsByYear W31243072562023 @default.
• W3124307256 crossrefType "journal-article" @default.
• W3124307256 hasAuthorship W3124307256A5018201073 @default.
• W3124307256 hasAuthorship W3124307256A5018716888 @default.
• W3124307256 hasAuthorship W3124307256A5024110076 @default.
• W3124307256 hasAuthorship W3124307256A5031888627 @default.
• W3124307256 hasAuthorship W3124307256A5032787375 @default.
• W3124307256 hasAuthorship W3124307256A5043942510 @default.
• W3124307256 hasAuthorship W3124307256A5058907248 @default.
• W3124307256 hasAuthorship W3124307256A5059240782 @default.
• W3124307256 hasAuthorship W3124307256A5069849278 @default.
• W3124307256 hasAuthorship W3124307256A5070028057 @default.
• W3124307256 hasAuthorship W3124307256A5073588989 @default.
• W3124307256 hasBestOaLocation W31243072561 @default.
• W3124307256 hasConcept C10515644 @default.
• W3124307256 hasConcept C126322002 @default.
• W3124307256 hasConcept C142462285 @default.
• W3124307256 hasConcept C151956035 @default.
• W3124307256 hasConcept C190139176 @default.
• W3124307256 hasConcept C203014093 @default.
• W3124307256 hasConcept C207103383 @default.
• W3124307256 hasConcept C2776185481 @default.
• W3124307256 hasConcept C3013748606 @default.
• W3124307256 hasConcept C44249647 @default.
• W3124307256 hasConcept C50382708 @default.
• W3124307256 hasConcept C71924100 @default.
• W3124307256 hasConceptScore W3124307256C10515644 @default.
• W3124307256 hasConceptScore W3124307256C126322002 @default.
• W3124307256 hasConceptScore W3124307256C142462285 @default.
• W3124307256 hasConceptScore W3124307256C151956035 @default.
• W3124307256 hasConceptScore W3124307256C190139176 @default.
• W3124307256 hasConceptScore W3124307256C203014093 @default.
• W3124307256 hasConceptScore W3124307256C207103383 @default.
• W3124307256 hasConceptScore W3124307256C2776185481 @default.
• W3124307256 hasConceptScore W3124307256C3013748606 @default.
• W3124307256 hasConceptScore W3124307256C44249647 @default.
• W3124307256 hasConceptScore W3124307256C50382708 @default.

• next